13 Nov 2025 | 3 Mins Read
Akums Drugs reports weak Q2 numbers, plans ₹200-cr Zambia investment
Flipitmoney
Akums Drugs and Pharmaceuticals Limited reported a 37.6% year-on-year decline in net profit to ₹41 crore for Q2FY25. Revenue dipped 1.5% to ₹1,017.5 crore, and EBITDA decreased by 22.4%. The company invested ₹200 crore in its Zambia-based subsidiary to establish a manufacturing facility and expand business operations in the African market.